Patients with previously untreated BRAF V600E/K–mutant metastatic melanoma were enrolled in this double-blinded phase III study of combination dabrafenib and trametinib (n = 211) vs dabrafenib plus placebo monotherapy (n = 212). Here, the authors here look at the efficacy and safety data following ≥36 months of follow-up. The 3-year progression-free survival was 22% in the dabrafenib plus trametinib group vs 12% in the monotherapy group (n = 212), and 3-year overall survival was 44% vs 32%, respectively.
The results show that dabrafenib plus trametinib combination therapy can produce durable survival benefits superior to those offered by dabrafenib alone and support its first-line use in this population.
https://www.ncbi.nlm.nih.gov/pubmed/28475671
